

Drug Utilization Review (DUR) Meeting Minutes

March 3, 2014

Members Present: Norman Byers, John Savageau, Jeffrey Hostetter, Peter Woodrow, Carrie Sorenson, Russ Sobotta, Tanya Schmidt, Steve Irsfeld, James Carlson, Michael Booth, Cheryl Huber

Members Absent: Todd Twogood, Leann Ness, Gary Betting, Carlotta McCleary

Medicaid Pharmacy Department: Brendan Joyce

J. Hostetter called the meeting to order at 1:00 p.m. J. Hostetter made a motion for J. Savageau to complete the chairman position vacated by G. Pfister. P. Woodrow seconded the motion. The motion passed with no audible dissent. Chair J. Savageau asked for a motion to approve the minutes from the December meeting. N. Byers moved that the minutes be approved, and J. Hostetter seconded the motion. Chair J. Savageau called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update

B. Joyce gave the budget update. For calendar year 2013, the net spend was approximately 19.5 million dollars. Prior to rebates, the amount was approximately 36.8 million dollars. Approximately 17.3 million dollars was received in rebates. January 2012 showed 80% generic utilization with the average paid per brand script costing approximately \$208 and the average paid per generic script costing approximately \$26. In January 2014, generic utilization was 85% with the average paid per brand script costing approximately \$290 and the average paid per generic script costing \$28.

Statins Second Review

A motion and second were made at the December meeting to place name-brand statins on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair J. Savageau called for a voice vote to approve the motion. The motion passed with no audible dissent.

Vecamyl Second Review

A motion and second were made at the December meeting to place Vecamyl on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair J. Savageau called for a voice vote to approve the motion. The motion passed with no audible dissent.

Coverage Clarification

B. Joyce informed the board that drugs that are not covered under pharmacy services will now be linked to a 'coverage clarification' document on the NDC drug lookup website. The document states, "The drug you selected is not covered under pharmacy services for North Dakota Medicaid. However, it is allowed under physician buy and bill services and should be billed by the physician's office."

Sylatron Review

This topic was tabled.

Cathflo Review

B. Joyce reviewed Cathflo information with the board. There was no public comment. P. Woodrow made a motion to place Cathflo on prior authorization. T. Schmidt seconded the motion. This topic will be reviewed at the next meeting.

Ketamine Powder Review

B. Joyce reviewed a Pharmaceutical Alert Bulletin from the U.S. Department of Health and Human Services/OIG discussing Ketamine powder. The board was informed that Ketamine will not be paid through pharmacy services.

Intranasal Cyanocobalamin Products Review

B. Joyce reviewed Nascobal information with the board. There was no public comment. M. Booth made a motion to place intranasal cyanocobalamin products on prior authorization. C. Huber seconded the motion. This topic will be reviewed at the next meeting.

Luzu Review

B. Joyce reviewed Luzu information with the board. There was no public comment. N. Byers made a motion to place Luzu on prior authorization. C. Sorenson seconded the motion. This topic will be reviewed at the next meeting.

Noxafil Review

B. Joyce reviewed Noxafil information with the board. There was no public comment. N. Byers made a motion to place Noxafil on prior authorization. S. Irsfeld seconded the motion. This topic will be reviewed at the next meeting.

Bethkis Review

B. Joyce reviewed Bethkis information with the board. There was no public comment. M. Booth made a motion to place Bethkis on prior authorization. N. Byers seconded the motion. This topic will be reviewed at the next meeting.

Update of New Drug Lookup Website

C. Rieth reviewed the enhanced NDC drug lookup website with the board. The website allows users to search for a drug by name or NDC number and it displays easy to understand results along with each drug's PA form.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. C. Huber moved to approve the new criteria and N. Byers seconded the motion. Chair J. Savageau called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held June 2, in Bismarck. N. Byers made a motion to adjourn the meeting. J. Hostetter seconded. The motion passed with no audible dissent. J. Savageau adjourned the meeting.